Effect Difference of Insulin Glargine Combined with Metformin Sustained-release Tablets,Acarbose and Premixed Insulin Combined with Acarbose in Treatment of Type 2 Diabetes Mellitus
Effect Difference of Insulin Glargine Combined with Metformin Sustained-release Tablets,Acarbose and Premixed Insulin Combined with Acarbose in Treatment of Type 2 Diabetes Mellitus
Objective To explore the clinical effect of insulin glargine combined with metformin sustained-release tablets and acarbose in the treatment of type 2 diabetes mellitus.Methods A total of eighty-four patients with type 2 diabetes mellitus admitted to Huaian Industrial Park People's Hospital from March 2020 to March 2023 were divided into control group(n=42)and observation group(n=42)according to random number table method.The control group was treated with premixed insulin and acarbose,and the observation group was treated with insulin glargine,metfor-min sustained-release tablets and acarbose.Blood glucose index,blood lipid index,islet β cell function and the occur-rence of adverse reactions were compared between the two groups.Results After treatment,the levels of glycated he-moglobin A1c,2-hour postprandial plasma glucose,fasting plasma glucose,total cholesterol,triglyceride,low-density cholesterol,fasting insulin and insulin resistance index in observation group were lower than those in control group,the level homeostasis model assessment-β was higher than that of control group,and the differences were statistically significant(all P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion Insulin glargine combined with acarbose and metformin sustained-release tablets can achieve better clini-cal effects in type 2 diabetes mellitus patients,regulate the level of glucose and lipid metabolism,improve the function of patients'islet beta cells,and the drug safety is good.
关键词
2型糖尿病/甘精胰岛素/二甲双胍/阿卡波糖/预混胰岛素/糖脂代谢
Key words
Type 2 diabetes mellitus/Insulin glargine/Metformin/Acarbose/Premixed insulin/Glycolipid metabo-lism
维普
万方数据